BridgeBio Pharma, Inc. (BBIO) Stock Forecast
Data as of Jun 16, 2026Healthcare · Current price $66.88 (-1.65%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Apr 8, 2026 | Luca Issi | RBC Capital | $100.00 | +49.5% |
| Mar 12, 2026 | Mani Foroohar | Leerink Partners | $98.00 | +46.5% |
| Feb 25, 2026 | Danielle Brill | Truist Financial | $95.00 | +42.0% |
| Feb 17, 2026 | Raghuram Selvaraju | H.C. Wainwright | $100.00 | +49.5% |
| Feb 13, 2026 | William Pickering | Tudor Pickering | $100.00 | +49.5% |
| Feb 13, 2026 | Trevor Allred | Oppenheimer | $83.00 | +24.1% |
| Feb 12, 2026 | Andrew Tsai | Jefferies | $100.00 | +49.5% |
| Feb 12, 2026 | Martin Auster | Raymond James | $89.00 | +33.1% |
| Jan 20, 2026 | Tiago Fauth | Wells Fargo | $88.00 | +31.6% |
| Oct 30, 2025 | Paul Choi | Goldman Sachs | $100.00 | +49.5% |
| Oct 27, 2025 | Mani Foroohar | Leerink Partners | $68.00 | +1.7% |
| Aug 29, 2025 | Raghuram Selvaraju | H.C. Wainwright | $70.00 | +4.7% |
| Apr 30, 2025 | Eliana Merle | UBS | $72.00 | +7.7% |
| Oct 24, 2024 | David Lebowitz | Citigroup | $45.00 | -32.7% |
| Oct 17, 2024 | Mani Foroohar | Leerink Partners | $46.00 | -31.2% |
| Sep 11, 2024 | Biren Amin | Piper Sandler | $46.00 | -31.2% |
| Sep 3, 2024 | Salim Syed | Mizuho Securities | $53.00 | -20.8% |
| Jun 24, 2024 | Danielle Brill | Raymond James | $46.00 | -31.2% |
| Jun 5, 2024 | Kostas Biliouris | BMO Capital | $37.00 | -44.7% |
| Jun 5, 2024 | Tiago Fauth | Wells Fargo | $58.00 | -13.3% |
Top Analysts Covering BBIO
BBIO vs Sector & Market
| Metric | BBIO | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.05 | 2.24 | 2.40 |
| Analyst Count | 21 | 8 | 19 |
| Target Upside | +57.3% | +11475.0% | +17.1% |
| P/E Ratio | -18.84 | 3.93 | 31.64 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $783M | $916M | $1.02B | 17 |
| 2027-03-31 | $238M | $287M | $333M | 6 |
| 2027-06-30 | $277M | $333M | $387M | 6 |
| 2027-09-30 | $312M | $376M | $436M | 6 |
| 2027-12-31 | $358M | $431M | $500M | 6 |
| 2028-03-31 | $408M | $491M | $570M | 6 |
| 2028-06-30 | $452M | $545M | $632M | 5 |
| 2028-09-30 | $503M | $605M | $702M | 5 |
| 2028-12-31 | $554M | $667M | $773M | 6 |
| 2029-12-31 | $2.52B | $3.33B | $3.92B | 15 |
| 2030-12-31 | $3.12B | $4.12B | $4.86B | 15 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-3.04 | $-1.92 | $-1.09 | 12 |
| 2027-03-31 | $-0.19 | $-0.15 | $-0.12 | 2 |
| 2027-06-30 | $0.02 | $0.03 | $0.03 | 2 |
| 2027-09-30 | $0.13 | $0.17 | $0.20 | 2 |
| 2027-12-31 | $0.27 | $0.34 | $0.41 | 2 |
| 2028-03-31 | $0.25 | $0.32 | $0.38 | 3 |
| 2028-06-30 | $0.39 | $0.50 | $0.61 | 3 |
| 2028-09-30 | $0.58 | $0.74 | $0.89 | 3 |
| 2028-12-31 | $0.76 | $0.97 | $1.17 | 3 |
| 2029-12-31 | $4.62 | $6.75 | $8.33 | 14 |
| 2030-12-31 | $6.08 | $8.88 | $10.96 | 14 |
Frequently Asked Questions
What is the analyst consensus for BBIO?
The consensus among 21 analysts covering BridgeBio Pharma, Inc. (BBIO) is Buy with an average price target of $99.86.
What is the highest price target for BBIO?
The highest price target for BBIO is $100.00, set by Luca Issi at RBC Capital on 2026-04-08.
What is the lowest price target for BBIO?
The lowest price target for BBIO is $17.00, set by Dane Leone at Raymond James on 2022-03-17.
How many analysts cover BBIO?
21 analysts have issued ratings for BridgeBio Pharma, Inc. in the past 12 months.
Is BBIO a buy or sell right now?
Based on 21 analyst ratings, BBIO has a consensus rating of Buy (2.05/5) with a +57.3% upside to the consensus target of $99.86.
What are the earnings estimates for BBIO?
Analysts estimate BBIO will report EPS of $-1.92 for the period ending 2026-12-31, with revenue estimated at $916M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.